{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:52:03Z","timestamp":1777614723573,"version":"3.51.4"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24_1220"],"award-info":[{"award-number":["KYCX24_1220"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX25_1210"],"award-info":[{"award-number":["KYCX25_1210"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62571264"],"award-info":[{"award-number":["62571264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62,171,236"],"award-info":[{"award-number":["62,171,236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117333","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T04:03:13Z","timestamp":1757736193000},"page":"117333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Comprehensive non-small cell lung cancer targets: From computational prediction to clinical breakthroughs in overcoming drug resistance"],"prefix":"10.1016","volume":"242","author":[{"given":"Wanjie","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0010","authenticated-orcid":false,"given":"Tingming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-a Cancer J. Clinic."},{"key":"10.1016\/j.bcp.2025.117333_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117333_b0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013Small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.bcp.2025.117333_b0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line immunotherapy for non\u2013small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0025","doi-asserted-by":"crossref","first-page":"e1504","DOI":"10.1002\/wcms.1504","article-title":"Current advances in ligand-based target prediction","volume":"11","author":"Yang","year":"2021","journal-title":"WIREs Comput. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2025.117333_b0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s43588-023-00530-2","article-title":"Learning on topological surface and geometric structure for 3D molecular generation","volume":"3","author":"Zhang","year":"2023","journal-title":"Nat. Comput. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101144","article-title":"Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions","volume":"15","author":"Wang","year":"2025","journal-title":"J. Pharm. Anal."},{"issue":"33","key":"10.1016\/j.bcp.2025.117333_b0040","doi-asserted-by":"crossref","first-page":"54548","DOI":"10.18632\/oncotarget.17408","article-title":"P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2025.117333_b0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semcancer.2021.02.012","article-title":"Targeting stemness of cancer stem cells to fight colorectal cancers","volume":"82","author":"Du","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"17","key":"10.1016\/j.bcp.2025.117333_b0060","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","article-title":"A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1","volume":"73","author":"Oike","year":"2013","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7555\/JBR.37.20230248","article-title":"Drug resistance mechanisms in cancers: Execution of pro-survival strategies","volume":"38","author":"Dhanyamraju","year":"2024","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib+ Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor\u2013mutated, MET-amplified non\u2013small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac059","article-title":"Multiview network embedding for drug-target interactions prediction by consistent and complementary information preserving","volume":"23","author":"Shang","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.18632\/aging.104204","article-title":"ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration","volume":"13","author":"Wang","year":"2021","journal-title":"Aging-Us"},{"issue":"11","key":"10.1016\/j.bcp.2025.117333_b0085","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1021\/ci300261r","article-title":"Similarity coefficients for binary chemoinformatics data: overview and extended comparison using simulated and real data sets","volume":"52","author":"Todeschini","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"W1","key":"10.1016\/j.bcp.2025.117333_b0090","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0095","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12859-022-05119-6","article-title":"Graph regularized non-negative matrix factorization with prior knowledge consistency constraint for drug\u2013target interactions prediction","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Bioinf."},{"issue":"21","key":"10.1016\/j.bcp.2025.117333_b0100","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.2174\/0929867324666170712115411","article-title":"Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches","volume":"26","author":"Jelica","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117333_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemolab.2022.104510","article-title":"Application of the LAD-LASSO as a dimensional reduction technique in the ANN-based QSAR study: discovery of potent inhibitors using molecular docking simulation","volume":"222","author":"Mozafari","year":"2022","journal-title":"Chemom. Intel. Lab. Syst."},{"key":"10.1016\/j.bcp.2025.117333_b0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eswa.2016.12.008","article-title":"Automatic selection of molecular descriptors using random forest: application to drug discovery","volume":"72","author":"Cano","year":"2017","journal-title":"Expert Syst. Appl."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/bioinformatics\/btab659","article-title":"Accelerating big data analysis through LASSO-Random forest algorithm in QSAR studies","volume":"38","author":"Motamedi","year":"2021","journal-title":"Bioinformatics"},{"issue":"14","key":"10.1016\/j.bcp.2025.117333_b0120","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.3390\/ijms241411488","article-title":"Recent advances in machine-learning-based chemoinformatics: a comprehensive review","volume":"24","author":"Niazi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2025.117333_b0125","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"issue":"7873","key":"10.1016\/j.bcp.2025.117333_b0130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2025.117333_b0135","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1021\/acs.jcim.1c00334","article-title":"DeepBSP-a machine learning method for accurate prediction of protein-ligand docking structures","volume":"61","author":"Bao","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2025.117333_b0140","series-title":"Progress in Molecular and Subcellular Biology","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-642-66626-1_4","article-title":"Three-Dimensional Pharmacophoric Pattern Searching","author":"Gund","year":"1977"},{"issue":"W1","key":"10.1016\/j.bcp.2025.117333_b0145","doi-asserted-by":"crossref","first-page":"W356","DOI":"10.1093\/nar\/gkx374","article-title":"PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s42256-022-00605-1","article-title":"Interpretable bilinear attention network with domain adaptation improves drug-target prediction","volume":"5","author":"Bai","year":"2023","journal-title":"Nat. Mach. Intell."},{"issue":"12","key":"10.1016\/j.bcp.2025.117333_b0155","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1109\/JBHI.2023.3315073","article-title":"Fusion-based deep learning architecture for detecting drug-target binding affinity using target and drug sequence and structure","volume":"27","author":"Wang","year":"2023","journal-title":"IEEE J. Biomed. Health Inform."},{"issue":"9","key":"10.1016\/j.bcp.2025.117333_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107646","article-title":"Overfit deep neural network for predicting drug-target interactions","volume":"26","author":"Xiaolin","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.bcp.2025.117333_b0165","series-title":"Biases of Drug\u2013Target Interaction Network Data","first-page":"23","author":"van Laarhoven","year":"2014"},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0170","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1021\/acsomega.4c08048","article-title":"Deep drug-target binding affinity prediction base on multiple feature extraction and fusion","volume":"10","author":"Li","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2025.117333_b0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jare.2023.10.014","article-title":"PROTAC derivatization of natural products for target identification and drug discovery: design of evodiamine-based PROTACs as novel REXO4 degraders","volume":"63","author":"Chen","year":"2024","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12915-024-02067-w","article-title":"Motif-guided identification of KRAS-interacting proteins","volume":"22","author":"Wu","year":"2024","journal-title":"BMC Biol."},{"key":"10.1016\/j.bcp.2025.117333_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2023.02.012","article-title":"FUNDC1 interacts with GPx4 to govern hepatic ferroptosis and fibrotic injury through a mitophagy-dependent manner","volume":"55","author":"Bi","year":"2024","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21037\/tlcr.2020.01.09","article-title":"Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer","volume":"9","author":"Zhu","year":"2020","journal-title":"Translational Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117333_b0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.bcp.2025.117333_b0200","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.1c01714","article-title":"Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.bcp.2025.117333_b0205","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-Mutated advanced non\u2013small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14728222.2017.1272582","article-title":"Targeting the EGFR T790M mutation in non-small-cell lung cancer","volume":"21","author":"Normanno","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2025.117333_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105787","article-title":"Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R\/T790M, and L858R\/T790M\/C797S forms of EGFR","volume":"147","author":"Todsaporn","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bcp.2025.117333_b0225","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112061","article-title":"Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)","volume":"189","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2025.117333_b0240","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0245","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12890-021-01553-z","article-title":"EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation","volume":"21","author":"Li","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.117333_b0250","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.3390\/cancers15174252","article-title":"IGF1R contributes to cell proliferation in ALK-mutated neuroblastoma with preference for activating the PI3K-AKT signaling pathway","volume":"15","author":"Guan","year":"2023","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.bcp.2025.117333_b0255","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bcp.2025.117333_b0260","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117333_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2024.125197","article-title":"Exploring the binding characteristics between lorlatinib and human alpha-1-acid glycoprotein: multispectral and molecular modeling techniques","volume":"326","author":"Sui","year":"2025","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"21","key":"10.1016\/j.bcp.2025.117333_b0275","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2025.117333_b0280","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-Mutant oncoproteins including lorlatinib-resistant compound mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2025.117333_b0285","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1556-0864(23)00335-0","article-title":"NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: the phase I\/II ALKOVE-1 study","volume":"18","author":"Johnson","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","author":"Lee","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117333_b0295","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non\u2013small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117333_b0300","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2025.117333_b0305","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1158\/1078-0432.CCR-14-0543","article-title":"LY2875358, a neutralizing and internalizing Anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.117333_b0310","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-16-1418","article-title":"A first-in-human phase i study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer","volume":"23","author":"Rosen","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"32","key":"10.1016\/j.bcp.2025.117333_b0315","doi-asserted-by":"crossref","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","article-title":"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent","volume":"110","author":"Merchant","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"32","key":"10.1016\/j.bcp.2025.117333_b0320","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.actbio.2024.04.029","article-title":"Adipocyte-targeted delivery of rosiglitazone with localized photothermal therapy for the treatment of diet-induced obesity in mice","volume":"181","author":"Zhang","year":"2024","journal-title":"Acta Biomater."},{"issue":"31","key":"10.1016\/j.bcp.2025.117333_b0330","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.23.02363","article-title":"Vebreltinib for advanced non\u2013small cell lung cancer harboring c-Met Exon 14 skipping mutation: a multicenter, single-arm, phase II KUNPENG study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7782","key":"10.1016\/j.bcp.2025.117333_b0335","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/d41586-019-03242-8","article-title":"Small molecule combats cancer-causing KRAS protein at last","volume":"575","author":"Herbst","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2025.117333_b0340","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf153","article-title":"KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape","volume":"30","author":"Frisch","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2025.117333_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.890247","article-title":"Light at the end of the tunnel: clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189108","article-title":"Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2025.117333_b0355","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.bcp.2025.117333_b0360","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0365","doi-asserted-by":"crossref","first-page":"F310","DOI":"10.1152\/ajprenal.00428.2016","article-title":"IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2\/STAT3 signaling pathway","volume":"313","author":"Xiao","year":"2017","journal-title":"Am. J. Physiol.-Renal Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117333_b0370","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0375","first-page":"14","article-title":"HDGF enhances VEGF-dependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in non-small cell lung cancer","volume":"44","author":"Eguchi","year":"2020","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0380","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5483\/BMBRep.2018.51.2.233","article-title":"Structure and function of vascular endothelial growth factor and its receptor system","volume":"51","author":"Park","year":"2018","journal-title":"BMB Rep."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0385","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"24","key":"10.1016\/j.bcp.2025.117333_b0390","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0395","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0400","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.lungcan.2020.06.016","article-title":"A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in chinese patients with advanced nonsquamous non-small-cell lung cancer - the FALUCA study","volume":"146","author":"Lu","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2025.117333_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107278","article-title":"Recent development of VEGFR small molecule inhibitors as anticancer agents: a patent review (2021\u20132023)","volume":"146","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2025.117333_b0410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.matbio.2020.05.004","article-title":"Cancer associated fibroblast: Mediators of tumorigenesis","volume":"91\u201392","author":"Alexander","year":"2020","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0415","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13578-023-01158-5","article-title":"Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition","volume":"13","author":"Samart","year":"2023","journal-title":"Cell Biosci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117333_b0420","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0425","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non\u2013small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5979","key":"10.1016\/j.bcp.2025.117333_b0430","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.1190310","article-title":"Tumor Immune Evasion","volume":"328","author":"Zindl","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.117333_b0440","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0445","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10027","key":"10.1016\/j.bcp.2025.117333_b0450","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.bcp.2025.117333_b0455","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bcp.2025.117333_b0460","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.bcp.2025.117333_b0465","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0470","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajco.12838","article-title":"Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis","volume":"14","author":"Man","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117333_b0475","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"issue":"15","key":"10.1016\/j.bcp.2025.117333_b0480","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/molecules24152804","article-title":"CA-170\u2013a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"issue":"15","key":"10.1016\/j.bcp.2025.117333_b0485","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1182\/blood-2008-01-133736","article-title":"CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80\/86 to promote tolerance","volume":"113","author":"Kurtz","year":"2009","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.bcp.2025.117333_b0490","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2019.37.15_suppl.8504","article-title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study","volume":"37","author":"Cascone","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0495","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-Line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0500","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Dubrovska","year":"2009","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.bcp.2025.117333_b0505","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4252\/wjsc.v15.i6.576","article-title":"Clinical relevance of stem cells in lung cancer","volume":"15","author":"Romeo","year":"2023","journal-title":"World J. Stem Cells."},{"issue":"11","key":"10.1016\/j.bcp.2025.117333_b0510","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.3390\/ijms24119437","article-title":"Natural cyclophilin a inhibitors suppress the growth of cancer stem cells in non-small cell lung cancer by disrupting crosstalk between CypA\/CD147 and EGFR","volume":"24","author":"Han","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9\u201310","key":"10.1016\/j.bcp.2025.117333_b0515","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12012-023-09803-8","article-title":"Targeting Retinol-Binding Protein 4 (RBP4) in the management of cardiometabolic diseases","volume":"23","author":"Oluwamodupe","year":"2023","journal-title":"Cardiovasc. Toxicol."},{"issue":"7269","key":"10.1016\/j.bcp.2025.117333_b0520","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0525","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12967-022-03823-8","article-title":"MTAP loss: a possible therapeutic approach for glioblastoma","volume":"20","author":"Patro","year":"2022","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117333_b0530","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Kumar","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0535","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.bcp.2025.117333_b0540","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-Cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.bcp.2025.117333_b0545","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.1021\/acs.jmedchem.2c00395","article-title":"Overview of methionine adenosyltransferase 2A (MAT2A) as an anticancer target: structure, function, and inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117333_b0550","doi-asserted-by":"crossref","first-page":"S766","DOI":"10.1016\/j.annonc.2022.07.620","article-title":"A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion","volume":"33","author":"Johnson","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: current status and future perspectives in non-small-cell lung cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117333_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217811","article-title":"SMARCA4: promises and challenges in the treatment of cancers","volume":"625","author":"Ye","year":"2025","journal-title":"Cancer Lett."},{"issue":"19","key":"10.1016\/j.bcp.2025.117333_b0565","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0570","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2025.117333_b0575","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"issue":"5827","key":"10.1016\/j.bcp.2025.117333_b0580","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bcp.2025.117333_b0585","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0590","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-rearranged non\u2013small cell lung cancer: results of an open-label, multicenter, phase 1B study","volume":"15","author":"Felip","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2025.117333_b0595","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0600","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor\u2013mutated, MET-amplified non\u2013small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0605","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117333_b0610","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1634\/theoncologist.2008-0276","article-title":"Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC","volume":"14","author":"Pennell","year":"2009","journal-title":"Oncologist"},{"issue":"15_suppl","key":"10.1016\/j.bcp.2025.117333_b0615","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7548","article-title":"A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens","volume":"30","author":"Zhang","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117333_b0620","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer[J]","volume":"376","author":"Mok","year":"2017","journal-title":"N. Eng. J. Med."},{"issue":"10072","key":"10.1016\/j.bcp.2025.117333_b0625","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2025.117333_b0630","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-Rearranged non-small cell lung cancer: results of an open-label, multicenter, phase 1B study","volume":"15","author":"Felip","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.117333_b0635","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2147\/OTT.S113435","article-title":"Salvage treatment with apatinib for advanced non-small-cell lung cancer","volume":"10","author":"Song","year":"2017","journal-title":"Oncotargets Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.117333_b0640","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117333_b0645","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117333_b0650","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non\u2013Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clinic Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2025.117333_b0655","doi-asserted-by":"crossref","first-page":"19460","DOI":"10.1002\/cam4.6548","article-title":"Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2025.117333_b0660","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ."},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0665","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12890-022-01981-5","article-title":"Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.bcp.2025.117333_b0670","unstructured":"L.L.C. Schrodinger, The PyMOL Molecular Graphics System, Version 1.8. In.; (2015)."},{"issue":"7","key":"10.1016\/j.bcp.2025.117333_b0675","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","article-title":"Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization","volume":"119","author":"Brozzo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.117333_b0680","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117333_b0685","doi-asserted-by":"crossref","first-page":"14369","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab","volume":"8","author":"Tan","year":"2017","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1016\/j.bcp.2026.117778","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:29:13Z","timestamp":1777411753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":137,"alternative-id":["S0006295225005982"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117333","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive non-small cell lung cancer targets: From computational prediction to clinical breakthroughs in overcoming drug resistance","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117333"}}